Eating Disorders

Eating Disorders β€” scientific infographic poster
🍽️ Interactive Visualization Hunger, Leptin & Why Diets Fight Back Watch the hunger neurons and the fullness neurons fight it out β€” then lose weight and see leptin fall, hunger climb and metabolism drop. It isn’t willpower. It’s a defended system. Launch →

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research and Advances
  12. Key Research Papers
  13. Featured Videos

1. Overview

Eating disorders are a group of serious psychiatric conditions characterized by persistent disturbances in eating behavior and the associated distressing thoughts and emotions. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) recognizes several distinct eating disorder diagnoses, the most prominent being Anorexia Nervosa (AN), Bulimia Nervosa (BN), Binge-Eating Disorder (BED), Avoidant/Restrictive Food Intake Disorder (ARFID), Pica, and Rumination Disorder. These conditions involve complex interactions between psychological, biological, and sociocultural factors, resulting in behaviors that severely compromise physical health, psychosocial functioning, and quality of life.

Eating disorders carry the highest mortality rate of any psychiatric illness. Anorexia nervosa has a standardized mortality ratio (SMR) of approximately 5.9, meaning affected individuals are nearly six times more likely to die prematurely compared to the general population. Deaths result from medical complications of malnutrition, purging behaviors, and suicide. Despite their severity, eating disorders remain significantly underdiagnosed and undertreated, with only approximately 20-30% of affected individuals receiving adequate treatment.

The DSM-5 (2013) brought significant changes to eating disorder classification, including the addition of Binge-Eating Disorder as a formal diagnosis (previously in the appendix), the removal of the amenorrhea criterion for anorexia nervosa, the reduction of binge/purge frequency threshold for bulimia nervosa from twice to once per week, and the introduction of ARFID as a new diagnosis replacing the childhood-limited "feeding disorder of infancy and early childhood." These changes improved diagnostic sensitivity and better captured the full spectrum of eating pathology.

2. Epidemiology

Anorexia Nervosa has a lifetime prevalence of approximately 0.9-1.4% in women and 0.1-0.3% in men. Peak age of onset is 15-19 years. AN is more common in industrialized countries and among Caucasian populations, though recent evidence suggests it occurs across all racial and ethnic groups. Incidence has remained relatively stable over the past several decades.

Bulimia Nervosa has a lifetime prevalence of approximately 1.0-1.5% in women and 0.1-0.5% in men. Mean age of onset is 18-21 years. BN incidence peaked in the 1980s-1990s and has subsequently declined in some Western countries, possibly reflecting a shift toward binge-eating disorder diagnoses.

Binge-Eating Disorder is the most common eating disorder, with a lifetime prevalence of 3.5% in women and 2.0% in men in the United States National Comorbidity Survey Replication (Hudson and colleagues, 2007). The gender ratio is more balanced than for AN or BN. Mean age of onset is 21-25 years, and BED is significantly more prevalent among individuals seeking obesity treatment (30-50%).

The World Health Organization World Mental Health Surveys (24,124 adults in 14 countries, 2013) found binge-eating disorder more common than bulimia nervosa (median lifetime prevalence 1.4% vs 0.8%). Binge-eating disorder lasted a median of about 4 years (bulimia about 6.5 years), and fewer than half of the people who had either disorder in their lifetime ever received treatment.

Eating disorders are increasingly recognized in males (accounting for approximately 25% of AN cases, 25-40% of BN cases, and 35-40% of BED cases), LGBTQ+ populations (2-4 fold elevated risk), athletes (particularly in aesthetic and weight-class sports), and across all racial and ethnic groups. The misconception that eating disorders primarily affect young, White, affluent women continues to contribute to diagnostic disparities.

3. Pathophysiology

Neurotransmitter Systems

Serotonergic dysfunction plays a central role in eating disorder pathophysiology. Individuals with AN show elevated 5-HT1A receptor binding and reduced 5-HT2A receptor binding in cortical regions, patterns that persist after weight restoration and may represent trait markers. Serotonin dysregulation contributes to the characteristic anxiety, perfectionism, obsessionality, and harm avoidance seen in AN. In BN, altered serotonergic function is linked to impulsivity and impaired satiety signaling. Dopaminergic dysfunction is also implicated, with AN patients showing altered striatal dopamine release contributing to anhedonia, aberrant reward processing, and paradoxical reward from starvation. BED is associated with reduced striatal dopamine D2 receptor availability, resembling patterns seen in substance addiction.

Appetite and Energy Homeostasis

Eating disorders involve profound disruption of the hormonal systems regulating hunger, satiety, and energy balance. In AN, ghrelin (the "hunger hormone") is paradoxically elevated while leptin (the satiety hormone) is markedly reduced, reflecting the body's attempt to counteract energy deficit. Peptide YY, cholecystokinin, and glucagon-like peptide-1 (GLP-1) (satiety signals) show variable alterations. These hormonal changes contribute to the peculiar absence of hunger drive in chronic AN despite severe caloric restriction. In BED, impaired postprandial satiety signaling and blunted ghrelin suppression after eating may contribute to binge episodes.

Brain Structure and Function

Neuroimaging reveals characteristic patterns across eating disorders. AN is associated with global gray matter volume reduction (partially reversible with weight restoration), altered insula function (interoceptive processing), and hyperactive dorsal cognitive control circuits with reduced ventral reward circuits, consistent with the ability to override hunger signals. BN and BED show impaired prefrontal inhibitory control and enhanced reward region activation to food cues, particularly in the ventral striatum and orbitofrontal cortex, paralleling neural patterns in addiction. Default mode network alterations across eating disorders correlate with body image disturbance and self-referential processing abnormalities.

Gut Microbiome

Emerging research demonstrates significant gut microbiome alterations in eating disorders. AN patients show reduced microbial diversity, increased representation of mucin-degrading bacteria (e.g., Akkermansia muciniphila), and altered short-chain fatty acid production. These changes may influence mood, appetite regulation, and immune function through the gut-brain axis. Microbiome composition partially normalizes with weight restoration but may not fully recover, potentially contributing to relapse vulnerability.

4. Etiology and Risk Factors

Genetic Factors

Psychological Factors

Sociocultural Factors

Trauma and Adversity

5. Clinical Presentation

Anorexia Nervosa

Restricting type: weight loss achieved primarily through dieting, fasting, and/or excessive exercise. Binge-eating/purging type: recurrent episodes of bingeing and/or purging (self-induced vomiting, laxative misuse). Clinical features include:

Bulimia Nervosa

Binge-Eating Disorder

ARFID (Avoidant/Restrictive Food Intake Disorder)

6. Diagnosis

DSM-5 Diagnostic Criteria for Anorexia Nervosa

Screening Tools

Medical Evaluation

A medical assessment usually includes:

7. Treatment

Treatment of Anorexia Nervosa

Nutritional rehabilitation and weight restoration are the foundation of AN treatment. Target weight gain of 0.5-1.0 kg/week for inpatient and 0.25-0.5 kg/week for outpatient settings. Monitoring for refeeding syndrome is critical during early weight restoration β€” characterized by hypophosphatemia, hypokalemia, hypomagnesemia, fluid shifts, and cardiac complications. Phosphorus supplementation is routinely provided.

Psychotherapy for AN:

Pharmacotherapy for AN: No medication has demonstrated robust efficacy for the core symptoms of AN or weight restoration. Olanzapine (2.5-10 mg/day) has modest evidence for weight gain and anxiety reduction. Selective serotonin reuptake inhibitors (SSRIs) are generally ineffective during the underweight state (likely due to tryptophan depletion) and have also been tested after weight restoration. In a 2006 randomized trial, 93 people with anorexia nervosa whose weight had been restored took fluoxetine or a placebo for up to one year, all with individual cognitive behavioral therapy: about the same share stayed well for the full year (26.5% on fluoxetine vs 31.5% on placebo), and fluoxetine did not delay relapse. The authors concluded the study "failed to demonstrate any benefit from fluoxetine" after weight restoration.

The American Psychiatric Association published a practice guideline for the treatment of patients with eating disorders in 2023.

Treatment of Bulimia Nervosa

Treatment of Binge-Eating Disorder

Levels of Care

8. Complications

9. Prognosis

Anorexia Nervosa: Long-term outcome studies (10-20 year follow-up) indicate that approximately 46% of patients achieve full recovery, 33% show improvement but remain symptomatic, and 21% develop a chronic course. The crude mortality rate is approximately 5-6% per decade of illness, with deaths due to medical complications (approximately 50%), suicide, and other causes. A 2011 meta-analysis of 36 studies counted about 5 deaths per 1,000 person-years in anorexia nervosa, 1.7 in bulimia nervosa and 3.3 in other eating disorders, and found that 1 in 5 people with anorexia nervosa who died had died by suicide. The standardized mortality ratio of 5.9 is the highest of any psychiatric disorder. Median time to recovery is approximately 7 years. Predictors of better outcome include younger age at onset, shorter duration of illness, and higher body mass index at presentation. Onset after age 25 and very low body mass index at presentation predict poorer outcomes.

Bulimia Nervosa: Approximately 55-70% of patients achieve full or partial remission over 5-10 years. The crude mortality rate is approximately 2% per decade. Crossover to AN occurs in approximately 10-15% of cases. Early treatment response (within the first 4-6 weeks of cognitive behavioral therapy) is a strong predictor of eventual outcome.

Binge-Eating Disorder: BED has the most favorable prognosis among eating disorders, with remission rates of approximately 50-80% over 4-5 years. However, weight management remains a significant challenge, and many patients continue to struggle with obesity-related medical complications even after binge cessation.

10. Prevention

11. Recent Research and Advances

Genomic and metabolomic discoveries have fundamentally reframed our understanding of anorexia nervosa. The Eating Disorders Working Group of the Psychiatric Genomics Consortium published landmark GWAS findings demonstrating that AN has significant metabo-psychiatric underpinnings β€” genetic risk factors overlap with metabolic traits (low body mass index, low insulin resistance) in addition to psychiatric disorders. This suggests AN should be reconceptualized as a metabo-psychiatric disorder rather than a purely psychological condition, with implications for treatment development targeting metabolic pathways.

Psilocybin-assisted therapy is being investigated for AN, with the rationale that psychedelic-induced cognitive flexibility and emotional processing may help overcome the rigid thinking patterns characteristic of AN. The published study so far is a small phase 1 open-label study (2023): 10 women with AN received a single 25-mg dose with psychological support. It was designed to test safety, not benefit; there were no clinically significant changes in heart tracing, vital signs or suicidal thinking, two women had low blood sugar without symptoms that cleared within 24 hours, and the authors judged the treatment safe, tolerable and acceptable. Whether it improves AN is not yet known; that needs larger controlled trials.

Gut microbiome-targeted interventions represent a novel treatment frontier. Fecal microbiota transplantation (FMT) is being studied in clinical trials for AN, with the hypothesis that restoring healthy gut microbial communities may improve appetite regulation, reduce gastrointestinal symptoms, and modulate brain function through the gut-brain axis. Probiotic supplementation trials are also underway.

Digital interventions are expanding treatment access. Internet-based cognitive behavioral therapy programs and a meal-logging smartphone app have shown efficacy comparable to guided self-help in reducing binge/purge symptoms. A chatbot app for eating disorder support is being evaluated in clinical trials. Smartphone-based ecological momentary interventions deliver personalized support at moments of vulnerability identified through real-time symptom monitoring.

Neuroimaging-guided treatments are advancing toward precision medicine. Real-time functional magnetic resonance imaging (fMRI) neurofeedback training patients to modulate activation in brain regions involved in self-referential processing and body image has shown promising preliminary results in AN. Repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex has been tested in BN and BED. A 2026 meta-analysis of brain-stimulation studies (rTMS and transcranial direct current stimulation) found a drop in food craving, based mainly on one single-session experiment, but no significant reduction in binge episodes, vomiting episodes or eating-disorder symptoms; the authors called these treatments investigational rather than therapeutic.

Key Research Papers

Historical Background

The earliest medical descriptions of self-starvation date to the medieval period, with accounts of "holy fasting" among female saints. Richard Morton provided the first medical case report of anorexia nervosa in 1689, describing a patient with "nervous consumption." The condition was independently described and named by Sir William Gull in London ("anorexia nervosa," 1873) and Charles Lasegue in Paris ("anorexie hysterique," 1873). Gerald Russell defined bulimia nervosa as a distinct syndrome in his landmark 1979 paper, describing an "ominous variant of anorexia nervosa." Albert Stunkard described binge eating in obese patients in 1959; in 1955 he had described the separate "night eating syndrome". Hilde Bruch's influential 1973 book Eating Disorders: Obesity, Anorexia Nervosa, and the Person Within transformed clinical understanding by emphasizing body image disturbance and deficits in interoceptive awareness as core psychopathology.

Key Research Papers

  1. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68(7):724-731. — doi:10.1001/archgenpsychiatry.2011.74
  2. Watson HJ, Yilmaz Z, Thornton LM, et al. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nat Genet. 2019;51(8):1207-1214. — doi:10.1038/s41588-019-0439-2
  3. Fairburn CG, Cooper Z, Doll HA, et al. Transdiagnostic cognitive-behavioral therapy for patients with eating disorders: a two-site trial with 60-week follow-up. Am J Psychiatry. 2009;166(3):311-319. — doi:10.1176/appi.ajp.2008.08040608
  4. Lock J, Le Grange D, Agras WS, et al. Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa. Arch Gen Psychiatry. 2010;67(10):1025-1032. — doi:10.1001/archgenpsychiatry.2010.128
  5. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904-914. — doi:10.1016/j.biopsych.2012.11.020
  6. Russell G. Bulimia nervosa: an ominous variant of anorexia nervosa. Psychol Med. 1979;9(3):429-448. — doi:10.1017/S0033291700031974
  7. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235-246. — doi:10.1001/jamapsychiatry.2014.2162
  8. Zipfel S, Giel KE, Bulik CM, et al. Anorexia nervosa: aetiology, assessment, and treatment. Lancet Psychiatry. 2015;2(12):1099-1111. — doi:10.1016/S2215-0366(15)00356-9
  9. Steinglass J, Foerde K, Kostro K, et al. Restrictive food intake as a choice β€” a paradigm for study. Int J Eat Disord. 2015;48(1):59-66. — doi:10.1002/eat.22345
  10. Frank GKW, Shott ME, DeGuzman MC. The neurobiology of eating disorders. Child Adolesc Psychiatr Clin N Am. 2019;28(4):629-640. — doi:10.1016/j.chc.2019.05.007
  11. Treasure J, Duarte TA, Schmidt U. Eating disorders. Lancet. 2020;395(10227):899-911. — doi:10.1016/S0140-6736(20)30059-3
  12. Stice E, Marti CN, Spoor S, et al. Dissonance and healthy weight eating disorder prevention programs: long-term effects from a randomized efficacy trial. J Consult Clin Psychol. 2008;76(2):329-340. — doi:10.1037/0022-006X.76.2.329
  13. Mack I, Cuntz U, Gramer C, et al. Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. Sci Rep. 2016;6:26752. — doi:10.1038/srep26752
  14. Bulik CM, Sullivan PF, Tozzi F, et al. Prevalence, heritability, and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry. 2006;63(3):305-312. — doi:10.1001/archpsyc.63.3.305
  15. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295(22):2605-2612. — doi:10.1001/jama.295.22.2605
  16. Ramanathan B, Vijayan S, Mohan M, et al. Non-invasive brain stimulation as an experimental treatment approach for bulimia nervosa and binge eating disorders: a meta-analysis and systematic review of literature. Indian J Psychiatry. 2026;68(5):411-428. — doi:10.4103/indianjpsychiatry_986_25
  17. Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1947-1953. — doi:10.1038/s41591-023-02455-9
  18. Crone C, Fochtmann LJ, Attia E, et al. The American Psychiatric Association practice guideline for the treatment of patients with eating disorders. Am J Psychiatry. 2023;180(2):167-171. — doi:10.1176/appi.ajp.23180001
  19. Stunkard AJ. Eating patterns and obesity. Psychiatr Q. 1959;33:284-295. — doi:10.1007/BF01575455
  20. Stunkard AJ, Grace WJ, Wolff HG. The night-eating syndrome; a pattern of food intake among certain obese patients. Am J Med. 1955;19(1):78-86. — doi:10.1016/0002-9343(55)90276-x

Back to Table of Contents

PubMed Topic Searches

  1. PubMed: anorexia nervosa treatment
  2. PubMed: bulimia nervosa CBT
  3. PubMed: binge eating disorder
  4. PubMed: eating disorder family based therapy
  5. PubMed: eating disorder epidemiology
  6. PubMed: eating disorder mortality
  7. PubMed: refeeding syndrome
  8. PubMed: eating disorder genetics
  9. PubMed: ARFID avoidant restrictive
  10. PubMed: eating disorder gut microbiome
  11. PubMed: eating disorder adolescents
  12. PubMed: eating disorder comorbidity

Back to Table of Contents

Connections

Back to Table of Contents